Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
NCT05220917
Unknown
To perform an observational analysis to emulate a target trial (i.e., a hypothetical pragmatic trial that would have answered the causal question of interest) comparing the effectiveness and safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide 1 receptor agonists (GLP-1RA), dipeptidyl peptidase-4 inhibitors (DPP-4i), and sulfonylureas (SU), at the class and individual agent level, in head-to-head comparisons in patients with type 2 diabetes (T2D).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2022
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Cardiovascular Events, Type2 Diabetes, Renal Disease
Register for Updates
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
NCT03987919
Completed
The reason for this study is to compare the effect of the study drug tirzepatide to semaglutide on blood sugar levels in participants with type 2 diabetes. The study will last approximately 47 weeks and may include about 12 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2022
Locations: NECCR PrimaCare Research, Fall River, Massachusetts +1 locations
Conditions: Type 2 Diabetes
Register for Updates
Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)
NCT03987074
Completed
The primary objective of this study is to evaluate the safety and tolerability of study drug(s) in participants with nonalcoholic steatohepatitis (NASH).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/25/2021
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Nonalcoholic Steatohepatitis
Register for Updates
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin
NCT03021187
Completed
This trial is conducted globally. The aim of the trial is to investigate the efficacy and safety of oral semaglutide versus placebo in subjects with Type 2 Diabetes Mellitus treated with insulin. All subjects should continue their pre-trial insulin therapy (basal, basal-bolus or premixed regimen including combinations of soluble insulins) throughout the trial. Subjects treated with metformin in addition to insulin treatment must continue their metformin treatment throughout the entire trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2020
Locations: Novo Nordisk Investigational Site, Boston, Massachusetts
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.
NCT02648204
Completed
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/02/2019
Locations: Novo Nordisk Investigational Site, Methuen, Massachusetts
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
NCT02461589
Completed
This trial is conducted globally. The aim of this trial is to investigate dose-finding of semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects with type 2 diabetes
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2019
Locations: Novo Nordisk Investigational Site, Boston, Massachusetts
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes
NCT01720446
Completed
This trial is conducted globally. The aim of the trial is to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes. The trial is event-driven, i.e. the maximum trial duration (up to max. 148 weeks) will depend on the accrual of major adverse cardiovascular events (MACE) in this trial and the remaining research programme. The incidence of MACE will be monitored throughout the trial which will be terminated according to plan when pre-specified stopp... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/20/2019
Locations: Novo Nordisk Investigational Site, Methuen, Massachusetts +1 locations
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes
NCT02305381
Completed
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of semaglutide once weekly versus placebo as add-on to basal insulin alone or basal insulin in combination with metformin in subjects with type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2019
Locations: Novo Nordisk Investigational Site, Waltham, Massachusetts
Conditions: Diabetes, Diabetes Mellitus, Type 2
Register for Updates